{"id":40572,"date":"2004-05-01T12:01:00","date_gmt":"2004-05-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/osteoporose-therapie-stand-2004"},"modified":"2004-05-01T12:01:00","modified_gmt":"2004-05-01T10:01:00","slug":"osteoporose-therapie-stand-2004","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/","title":{"rendered":"Osteoporose-Therapie &#8211; Stand 2004"},"content":{"rendered":"<p>Zusammenfassung: Die Pharmakotherapie der Osteoporose ist in den letzten zehn Jahren \u00fcbersichtlicher geworden. Neben der Basistherapie mit Kalzium und Vitamin D3 haben sich Bisphosphonate in randomisierten kontrollierten Studien als wirksam erwiesen, Frakturen zu verhindern. Die sogenannte Hormonersatz-Therapie ist wegen ihrer UAW als generelle Sekund\u00e4rpr\u00e4vention der Osteoporose f\u00fcr Frauen in der Postmenopause nicht mehr zu empfehlen. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Die Pharmakotherapie der Osteoporose ist in den letzten zehn Jahren \u00fcbersichtlicher geworden. Neben der Basistherapie mit Kalzium und Vitamin D3 haben sich Bisphosphonate in randomisierten kontrollierten Studien als wirksam erwiesen, Frakturen zu verhindern. Die sogenannte Hormonersatz-Therapie ist wegen ihrer UAW als generelle Sekund\u00e4rpr\u00e4vention der Osteoporose f\u00fcr Frauen in der Postmenopause nicht mehr zu empfehlen. [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[3968,4040,1789,1694,393,394,4899,4911,4995,5225,1104,5853,756,6087,6131,6351,6424,6503,6504,7041,395],"class_list":["post-40572","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-alendronat","tag-anabolika","tag-bisphosphonate","tag-calcitonin","tag-cholecalciferol","tag-colecalciferol","tag-estrogene-gestagene","tag-etidronat","tag-fit-studie","tag-hip-studie","tag-kalzium","tag-more-studie","tag-osteoporose","tag-oestrogene-gestagene","tag-parathormon","tag-proof-studie","tag-raloxifen","tag-risedronat","tag-risedronsaeure","tag-vert-studie","tag-vitamin-d"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Osteoporose-Therapie - Stand 2004 - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Osteoporose-Therapie - Stand 2004 - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Zusammenfassung: Die Pharmakotherapie der Osteoporose ist in den letzten zehn Jahren \u00fcbersichtlicher geworden. Neben der Basistherapie mit Kalzium und Vitamin D3 haben sich Bisphosphonate in randomisierten kontrollierten Studien als wirksam erwiesen, Frakturen zu verhindern. Die sogenannte Hormonersatz-Therapie ist wegen ihrer UAW als generelle Sekund\u00e4rpr\u00e4vention der Osteoporose f\u00fcr Frauen in der Postmenopause nicht mehr zu empfehlen. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2004-05-01T10:01:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2004\/05\/Abbildung-2004-33-5.gif\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"17\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/osteoporose-therapie-stand-2004\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/osteoporose-therapie-stand-2004\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Osteoporose-Therapie &#8211; Stand 2004\",\"datePublished\":\"2004-05-01T10:01:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/osteoporose-therapie-stand-2004\\\/\"},\"wordCount\":3365,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/osteoporose-therapie-stand-2004\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2004\\\/05\\\/Abbildung-2004-33-5.gif\",\"keywords\":[\"Alendronat\",\"Anabolika\",\"Bisphosphonate\",\"Calcitonin\",\"Cholecalciferol\",\"Colecalciferol\",\"Estrogene\\\/Gestagene\",\"Etidronat\",\"FIT-Studie\",\"HIP-Studie\",\"Kalzium\",\"MORE-Studie\",\"Osteoporose\",\"\u00d6strogene\\\/Gestagene\",\"Parathormon\",\"PROOF-Studie\",\"Raloxifen\",\"Risedronat\",\"Risedrons\u00e4ure\",\"VERT-Studie\",\"Vitamin D\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/osteoporose-therapie-stand-2004\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/osteoporose-therapie-stand-2004\\\/\",\"name\":\"Osteoporose-Therapie - Stand 2004 - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/osteoporose-therapie-stand-2004\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/osteoporose-therapie-stand-2004\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2004\\\/05\\\/Abbildung-2004-33-5.gif\",\"datePublished\":\"2004-05-01T10:01:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/osteoporose-therapie-stand-2004\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/osteoporose-therapie-stand-2004\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/osteoporose-therapie-stand-2004\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2004\\\/05\\\/Abbildung-2004-33-5.gif\",\"contentUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2004\\\/05\\\/Abbildung-2004-33-5.gif\",\"width\":500,\"height\":266},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/osteoporose-therapie-stand-2004\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Osteoporose-Therapie &#8211; Stand 2004\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Osteoporose-Therapie - Stand 2004 - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/","og_locale":"de_DE","og_type":"article","og_title":"Osteoporose-Therapie - Stand 2004 - Der Arzneimittelbrief","og_description":"Zusammenfassung: Die Pharmakotherapie der Osteoporose ist in den letzten zehn Jahren \u00fcbersichtlicher geworden. Neben der Basistherapie mit Kalzium und Vitamin D3 haben sich Bisphosphonate in randomisierten kontrollierten Studien als wirksam erwiesen, Frakturen zu verhindern. Die sogenannte Hormonersatz-Therapie ist wegen ihrer UAW als generelle Sekund\u00e4rpr\u00e4vention der Osteoporose f\u00fcr Frauen in der Postmenopause nicht mehr zu empfehlen. [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2004-05-01T10:01:00+00:00","og_image":[{"url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2004\/05\/Abbildung-2004-33-5.gif","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe","Gesch\u00e4tzte Lesezeit":"17\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Osteoporose-Therapie &#8211; Stand 2004","datePublished":"2004-05-01T10:01:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/"},"wordCount":3365,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2004\/05\/Abbildung-2004-33-5.gif","keywords":["Alendronat","Anabolika","Bisphosphonate","Calcitonin","Cholecalciferol","Colecalciferol","Estrogene\/Gestagene","Etidronat","FIT-Studie","HIP-Studie","Kalzium","MORE-Studie","Osteoporose","\u00d6strogene\/Gestagene","Parathormon","PROOF-Studie","Raloxifen","Risedronat","Risedrons\u00e4ure","VERT-Studie","Vitamin D"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/","name":"Osteoporose-Therapie - Stand 2004 - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2004\/05\/Abbildung-2004-33-5.gif","datePublished":"2004-05-01T10:01:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/#primaryimage","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2004\/05\/Abbildung-2004-33-5.gif","contentUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2004\/05\/Abbildung-2004-33-5.gif","width":500,"height":266},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/osteoporose-therapie-stand-2004\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Osteoporose-Therapie &#8211; Stand 2004"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=40572"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40572\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=40572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=40572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=40572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}